Hospital
Good Samaritan Hospital, L.P.
Good Samaritan Hospital, L.P. was paid $5.26M by Medicaid between Jan 2018 and Dec 2024, across 113 billing codes. Its largest line is 0450, Emergency room services — 41% of everything it billed.
33Billing provider infoGOOD SAMARITAN HOSPITAL, L.P.
SAN JOSE, CA 95124
SAN JOSE, CA 95124
33aNPI1437103777assigned 05/20/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.26M
24GClaims236,680
24DCodes billed113
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#221 of 410
Median peer was paid$6.90M
This provider vs. median0.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 56,737 | $1.61M | |
| 2019 | 35,412 | $689K | |
| 2020 | 23,344 | $223K | |
| 2021 | 29,037 | $228K | |
| 2022 | 32,427 | $445K | |
| 2023 | 30,226 | $912K | |
| 2024incomplete | 29,497 | $1.16M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 41% | 57,816 | 53,411 | $2.15M |
| 0270 | 13% | 20,537 | 11,528 | $672K | |
| 0250 | 6.4% | 6,332 | 4,177 | $336K | |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 5.5% | 1,873 | 1,573 | $290K |
| J3490 | Unclassified drugs | 5.2% | 2,507 | 2,133 | $273K |
| 80053 | Comprehensive metabolic panel | 4.5% | 8,392 | 7,868 | $237K |
| 80048 | Basic metabolic panel (calcium, ionized) | 3.9% | 7,351 | 6,611 | $204K |
| 99199 | Unlisted special service, procedure or report | 3.4% | 1,490 | 1,440 | $176K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 3,853 | 3,409 | $124K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 673 | 271 | $54K |
| 71046 | Radiologic examination, chest; 2 views | 1.0% | 1,722 | 1,658 | $54K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 1,472 | 1,429 | $51K |
101 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 5,492 | $50K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,345 | $39K |
| 85027 | <1% | 19,890 | $37K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,570 | $35K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,564 | $31K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,682 | $31K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,101 | $29K |
| 81003 | <1% | 3,983 | $29K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,498 | $26K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 823 | $26K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 374 | $19K |
| 84484 | <1% | 4,627 | $17K | |
| 99283 | Emergency room visit (moderate) | <1% | 450 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,447 | $16K |
| 87081 | <1% | 319 | $15K | |
| 87632 | <1% | 176 | $14K | |
| 87430 | <1% | 322 | $12K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 207 | $10K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 686 | $10K |
| 73562 | <1% | 84 | $8K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 421 | $8K |
| 73610 | <1% | 125 | $8K | |
| 0272 | <1% | 1,526 | $8K | |
| 87077 | <1% | 314 | $7K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 104 | $7K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,164 | $7K |
| 83690 | <1% | 5,641 | $7K | |
| 73630 | <1% | 124 | $7K | |
| 81001 | <1% | 2,562 | $6K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 377 | $6K |
| 84702 | <1% | 239 | $6K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 322 | $6K |
| 87400 | <1% | 84 | $5K | |
| 80305 | <1% | 193 | $5K | |
| 36416 | <1% | 181 | $5K | |
| 81025 | <1% | 791 | $4K | |
| 99284 | Emergency room visit (serious) | <1% | 215 | $4K |
| 82553 | <1% | 1,464 | $4K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 572 | $4K |
| 84703 | <1% | 2,289 | $3K | |
| 87486 | <1% | 403 | $3K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 212 | $3K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 268 | $3K |
| 82550 | <1% | 1,866 | $3K | |
| 80076 | <1% | 2,443 | $3K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 777 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 437 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 202 | $3K |
| 85610 | <1% | 786 | $3K | |
| 83735 | <1% | 927 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,423 | $2K |
| 87040 | <1% | 1,134 | $2K | |
| 82248 | <1% | 3,739 | $2K | |
| 85730 | <1% | 432 | $2K | |
| 86901 | <1% | 320 | $2K | |
| 85007 | <1% | 1,635 | $1K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 105 | $1K |
| 73140 | <1% | 12 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,880 | $1K |
| 83880 | <1% | 966 | $932.98 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12 | $925.92 |
| 72100 | <1% | 27 | $907.82 | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 54 | $848.00 |
| 73130 | <1% | 14 | $632.82 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,815 | $527.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 724 | $518.35 |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 29 | $511.87 |
| 86900 | <1% | 320 | $502.39 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 967 | $462.78 |
| 83605 | <1% | 1,068 | $449.56 | |
| 87186 | <1% | 365 | $441.54 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 424 | $389.05 |
| 87581 | <1% | 403 | $361.01 | |
| 73030 | <1% | 12 | $327.27 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 403 | $320.72 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 343 | $317.75 |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 37 | $313.33 |
| 96376 | <1% | 634 | $301.67 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 468 | $277.19 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 15 | $237.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 275 | $230.30 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 115 | $213.48 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $166.51 |
| 76830 | Ultrasound, transvaginal | <1% | 103 | $155.26 |
| 85379 | <1% | 94 | $146.71 | |
| 86850 | <1% | 30 | $120.51 | |
| A9270 | Non-covered item or service | <1% | 763 | $73.09 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 35 | $57.09 |
| 87420 | <1% | 72 | $54.94 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 213 | $50.29 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 17 | $40.46 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 72 | $31.80 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 73 | $31.80 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 74 | $19.61 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 134 | $19.28 |
| 80306 | <1% | 39 | $15.96 | |
| 87147 | <1% | 13 | $5.11 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 14 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 24 | $0.00 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 0% | 27 | $0.00 |
| 90715 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWARE, BRANDON (CFO)